Rihe Liu
Overview
Explore the profile of Rihe Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1802
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ge R, Liu R, He M, Wu J, Zhang F, Huang C
Front Neurol
. 2025 Jan;
15:1500709.
PMID: 39758782
Objective: To systematically evaluate the clinical efficacy of acupuncture in the treatment of diabetic peripheral neuropathy (DPN). Methods: Randomized controlled trial (RCT) of acupuncture for diabetic peripheral neuropathy in Chinese...
2.
Wang Y, Li S, Hu M, Yang Y, McCabe E, Zhang L, et al.
Nat Nanotechnol
. 2024 Aug;
19(8):1235.
PMID: 39117909
No abstract available.
3.
Wang Y, Li S, Hu M, Yang Y, McCabe E, Zhang L, et al.
Nat Nanotechnol
. 2024 Mar;
19(6):856-866.
PMID: 38480836
The efficacy of STING (stimulator of interferon genes) agonists is due to various factors, primarily inefficient intracellular delivery, low/lack of endogenous STING expression in many tumours, and a complex balance...
4.
Development of F-Labeled hydrophilic -cyclooctene as a bioorthogonal tool for PET probe construction
Xu M, Ma X, Pigga J, Zhang H, Wang S, Zhao W, et al.
Chem Commun (Camb)
. 2023 Oct;
59(97):14387-14390.
PMID: 37877355
We report the development of a hydrophilic F-labeled a-TCO derivative [F]3 (log = 0.28) through a readily available precursor and a single-step radiofluorination reaction (RCY up to 52%). We demonstrated...
5.
Ligand-installed polymeric nanocarriers for combination chemotherapy of EGFR-positive ovarian cancer
Xi X, Lei F, Gao K, Li J, Liu R, Karpf A, et al.
J Control Release
. 2023 Jul;
360:872-887.
PMID: 37478915
Combination chemotherapeutic drugs administered via a single nanocarrier for cancer treatment provides benefits in reducing dose-limiting toxicities, improving the pharmacokinetic properties of the cargo and achieving spatial-temporal synchronization of drug...
6.
Liu X, Zhou J, Wu H, Chen S, Zhang L, Tang W, et al.
Mol Ther
. 2022 Sep;
31(1):119-133.
PMID: 36146933
The local microenvironment where tumors develop can shape cancer progression and therapeutic outcome. Emerging evidence demonstrate that the efficacy of immune-checkpoint blockade (ICB) is undermined by fibrotic tumor microenvironment (TME)....
7.
Shen L, Li J, Liu Q, Das M, Song W, Zhang X, et al.
J Control Release
. 2022 Feb;
343:303-313.
PMID: 35104570
Interactions between different cell types in the tumor microenvironment (TME) affect tumor growth. Tumor-associated fibroblasts produce C-X-C motif chemokine ligand 13 (CXCL13) which recruits B cells to the TME. B-cells...
8.
Wang Y, Tiruthani K, Li S, Hu M, Zhong G, Tang Y, et al.
Adv Mater
. 2021 May;
33(23):e2007603.
PMID: 33945178
Liver malignancies are among the tumor types that are resistant to immune checkpoint inhibition therapy. Tumor-associated macrophages (TAMs) are highly enriched and play a major role in inducing immunosuppression in...
9.
Liu Y, Tiruthani K, Wang M, Zhou X, Qiu N, Xiong Y, et al.
Nanoscale Horiz
. 2021 Feb;
6(4):319-329.
PMID: 33587080
Adipocytes are the primary cellular components within the tumor microenvironment (TME) of triple-negative breast cancer (TNBC). Increasing evidence suggests that tumor-associated adipocytes (TAAs) can aggravate tumor progression, exacerbate the immunosuppressive...
10.
Das M, Zhou X, Liu Y, Das A, Vincent B, Li J, et al.
Transl Oncol
. 2020 Aug;
13(12):100856.
PMID: 32862105
The immunogenic clonal-fraction threshold in heterogeneous solid-tumor required to induce effective bystander-killing of non-immunogenic subclones is unknown. Pancreatic cancer poses crucial challenges for immune therapeutic interventions due to low mutational-burden...